Influence of Methylprednisolone Pulse Therapy on Liver Function in Patients with Graves’ Orbitopathy

Table 3

Range of parameters in DON group with increased aminotransferases or total bilirubin level.

DON group
Patient	Age	ALT (7–56 U/L)						AST (5–40 U/L)						TB (3.42–20.52 μmol/L)
		B0	B1	C0	C1	C2	C3	B0	B1	C0	C1	C2	C3	B0	B1	C0	C1	C2	C3
1	76	38	55	21	23	25	31	34	44	25	21	21	24	22.74	16.07	8.89	9.75	11.80	17.10
2	65	45	43	20	22	29	18	28	17	20	19	14	12	26.85	16.07	20.18	17.96	22.06	16.42
3	31	24	193	11	19	21	—	21	104	18	26	21	—	24.11	21.34	15.56	16.07	24.45	—
4	74	18	238	14	15	17	18	17	94	15	13	12	12	21.72	11.29	20.18	19.67	13.68	7.87
5	69	16	95	41	37	28	33	26	57	23	25	12	14	14.54	6.16	9.23	9.23	7.70	8.21
6	76	32	66	25	36	33	21	37	76	29	31	32	18	8.04	6.84	6.33	7.01	6.16	8.38
7	50	39	112	32	26	21	16	35	43	21	17	9	13	4.62	7.18	9.41	7.87	5.64	7.35
8	69	24	103	22	25	17	19	12	88	18	12	12	14	12.65	16.07	10.94	13.51	20.52	11.80

Values above the upper limit of normal are shown in bold. 4-Fold increase of aminotransferase concentrations in comparison to initial values. ALT—alanine aminotransferase; AST—aspartate aminotransferase; TB—total bilirubin; B0—before treatment; B1—after administration of 3.0 g IVMP; C0—before continuation of treatment with additional 12 pulses of IVMP in every week schedule (4.5 g IVMP); C1—after administration of additional 0.5 g IVMP; C2—after administration of additional 3.0 g IVMP; C3—after administration of additional 4.5 g IVMP; DON—dysthyroid optic neuropathy; IVMP—intravenous methylprednisolone.